Satellos Bioscience Stock Today
| MSCL Stock | 10.98 -0.57 -4.94% |
Performance Moderate
| Odds Of Distress Low
|
Trading activity places Satellos Bioscience at $10.98, translating to 4.94% down in today's trading. Credit and volatility analytics assign Satellos Bioscience a 21% risk of financial distress over the forecast horizon. On a risk-adjusted basis, Satellos Bioscience has produced modest risk-adjusted performance over the last 90 trading days, consistent with moderate return metrics. Satellos Bioscience has reported 12 for 1 split on 30th of January 2026. The performance scores are computed for the period from December 16, 2025 through March 16, 2026. Learn more.
Moving against Satellos Stock
Stock Highlights
Satellos Bioscience (MSCL) is listed on Toronto Exchange in Canada. The company operates in the Biotechnology industry (Healthcare sector). Satellos Bioscience enters market cap screens as a small-cap name with total equity value near 226.48 M across biotechnology companies. To frame that market cap reading, note enterprise value near 179.29 M, about 20.63 M shares outstanding, and a workforce of about 14 people. The company has 21.05 K shares sold short (0.63 days to cover). The company has return on total asset (ROA) of -54.25 % implying that asset-level returns are negative, losing $54.25 per $100. This lags far behind comparable companies. Similarly, it shows a return on equity (ROE) of -87.59 %, indicating that the business is consuming rather than creating equity value. Satellos Bioscience financial stability analysis Ownership Allocation Satellos Bioscience holds a 6.2% of its outstanding shares held by insiders and 6.19% owned by institutional investors. Of Satellos Bioscience's outstanding shares, about 6% are institutional, 6% insider-held, and 88% in the public float. Check Satellos Ownership DetailsFor Satellos Bioscience, the highlight set condenses the main operating, valuation, and market signals into a faster research view. Current market capitalization is about 226.48 Million.
Notable Updates
| CEO, CoFounder | Francis MBA |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Common Risk Profiles
Standard volatility measures are as important as alpha and beta when evaluating Satellos Bioscience's performance and investment risk in the broader market context.
| Mean Deviation | 4.13 | |||
| Semi Deviation | 5.52 | |||
| Standard Deviation | 5.61 | |||
| Variance | 31.45 |
Satellos Bioscience Against Markets
Stock Analysis Notes
The book value of the company was now reported as 3.04. The company had not issued any dividends in recent years. Satellos Bioscience completed a 1:12 stock split on 30th of January 2026. Latest disclosures for Satellos Bioscience show $73.0 million in Total Assets.Investor Insights and Alerts
| Satellos Bioscience is way too risky over 90 days horizon | |
| Satellos Bioscience appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was -28.1 M with loss before overhead, payroll, taxes, and interest of -16.68 M. | |
| Satellos Bioscience has accumulated about 40.07 M in cash with -24.98 M of positive cash flow from operations. |
Market Capitalization
Satellos Bioscience enters market cap screens as a small-cap name with total equity value near 226.48 M across biotechnology companies. To frame that market cap reading, note enterprise value near 179.29 M, about 20.63 M shares outstanding, and a workforce of about 14 people.Technical Drivers
As of the 16th of March 2026, Satellos Bioscience maintains a quoted price of 10.98 per share. Short-term indicators show Coefficient Of Variation of 836.3, risk adjusted performance of 0.1043, and Semi Deviation of 5.52. The model measures trend continuation and reversal probability using historical patterns. Comparative analytics measure deviation from sector averages.Satellos Bioscience Price Movement Analysis
Transformation |
This analysis covers sixty-one data points across the selected time horizon. Satellos Bioscience Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe Satellos Bioscience price patterns.
Outstanding Bonds
Outstanding bonds linked to Satellos Bioscience can tell investors a great deal about how the company finances itself beyond common equity markets. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Predictive Daily Indicators
For active positions in Satellos Bioscience, intraday indicators can reveal when the market is confirming a move and when the move is losing sponsorship. For most traders, the advantage is faster feedback on market participation and momentum, which can sharpen both entries and exits.
Forecast Models
Time-series forecasting models for Satellos Bioscience analyze previously observed prices and returns to estimate how the stock may behave under similar statistical conditions. These models are descriptive, not prophetic, so the real discipline comes from checking whether the market regime has changed enough to make the old pattern less reliable.Stock Overview, Methodology & Data Sources
The stock recently underwent a stock split. Satellos Bioscience has reported 12 for 1 split on 30th of January 2026. This stock section frames Satellos Bioscience within its peer set and highlights how fundamentals align with price behavior. Current metrics include P/B of 4.9. Satellos Bioscience has a market cap of 226.48 M, ROE of -87.59%.
Methodology
Unless otherwise specified, financial data for Satellos Bioscience is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Satellos (CA:MSCL) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs rely on public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR. Publication cadence can introduce timing differences. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Satellos Bioscience may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardBe your own money manager
Serious investors usually evaluate Satellos Bioscience in portfolio context because a good security can still be a weak addition if it increases concentration or unnecessary volatility. This is most useful when investors want to improve risk-adjusted return instead of simply owning more ideas at once.
Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
Satellos Bioscience Corporate Management
Governance context around Satellos Bioscience gives investors another way to assess whether decision-making power is balanced, accountable, and aligned with shareholder priorities. This becomes more valuable when investors want to compare oversight quality across firms that may otherwise look financially similar.
| Michael MBA | Chief Officer | Profile | |
| Philip MA | Chief Officer | Profile | |
| CPA CMA | Head Strategy | Profile | |
| Ryan Mitchell | Senior Development | Profile | |
| Desiree Chan | Chief Staff | Profile |
More Resources for Satellos Stock Analysis
Other Information on Investing in Satellos Stock
Financial ratios for Satellos Bioscience provide valuation context across profits, cash flow, and enterprise value. They help compare Satellos to other measures in a consistent way.